Novartis Pharmaceuticals v. Accord Healthcare Inc.

Opinion

Case: 21-1070 Document: 43 Page: 1 Filed: 01/04/2022

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

______________________

January 4, 2022

ERRATA

______________________

Appeal No. 21-1070

NOVARTIS PHARMACEUTICALS CORPORATION, Plaintiff-Appellee

v.

ACCORD HEALTHCARE, INC., AUROBINDO PHARMA LTD., AUROBINDO PHARMA USA, INC., DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD., EMCURE PHARMACEUTICALS LTD., HERITAGE PHARMACEUTICALS INC., GLENMARK PHARMACEUTICALS INC., USA, GLENMARK PHARMACEUTICALS LIMITED, HETERO USA, INC., HETERO LABS LIMITED UNIT-V, HETERO LABS LIMITED, MYLAN PHARMACEUTICALS, INC., PRINSTON PHARMACEUTICAL INC., STRIDES GLOBAL PHARMA PRIVATE LIMITED, STRIDES PHARMA, INC., TORRENT PHARMA INC., TORRENT PHARMACEUTICALS LTD., ZYDUS PHARMACEUTICALS (USA) INC., CADILA HEALTHCARE LTD., APOTEX INC., APOTEX CORP., SUN PHARMACEUTICAL INDUSTRIES, LTD., SUN PHARMACEUTICAL INDUSTRIES INC.,

Case: 21-1070 Document: 43 Page: 2 Filed: 01/04/2022

2 NOVARTIS PHARMACEUTICALS v. ACCORD HEALTHCARE INC.

SUN PHARMA GLOBAL FZE, Defendants

HEC PHARM CO., LTD., HEC PHARM USA INC., Defendants-Appellants

Decided: January 3, 2022 Precedential opinion

______________________

Please make the following change:

Page 2, line 7 (majority opinion): the issuance date of “January 3, 2021” is changed to “January 3, 2022”.